

Outthink. Outperform.

## 1Q19: In-line results supported by Singapore

Kelington's (KGB) 1Q19 core net profit was in line with consensus and our forecasts, making up 22% of both respective full-year estimates. The commendable result was mainly driven by UHP projects in Singapore, which garner higher margins. We maintain our BUY call and raise our target price to RM1.72.

### 1Q19 results came in within expectations

KGB's headline net profit came in at RM4.8m (+15% yoy) in 1Q19. After excluding a RM0.6m unrealized forex loss and RM0.2m impairment on trade receivables, core net profit doubled to RM5.6m (vs. RM2.7m in 1Q18 after excluding a one-off settlement gain from Biocon). UHP business saw lower revenue of RM44m (-31% yoy) as a result of a lower contribution from a large UHP project in China, which was partly offset by a stronger Singapore operation. UHP business continues to contribute the bulk of group revenue. **Process Engineering (PE)** revenue rose 43% yoy to RM20.8m, attributed to the larger projects completed in Malaysia. Collectively, these two divisions accounted for 85% of KGB's total revenue while General Contracting (GC) and Industrial Gases contributed 13% and 2% respectively.

### Singapore made up 41% of 1Q19 revenue (vs. 16% in 1Q18)

Revenue fell 12% yoy to RM76.4m due to a lower contribution from China (-53% yoy). However, revenue was supported by a rise in UHP projects in Singapore (+128% yoy), which was the largest contributor at 41% of group revenue in 1Q19. As a result of the higher revenue from Singaporean projects, gross and net profit margins both rose to 18.3% (from 14.1%) and 6.3% (from 4.9%) respectively.

### Order book update

The total outstanding order book stood at RM330m with RM146m of new orders secured YTD. UHP made up the bulk of the order book at 79% of the total, followed by PE and GC at 16% and 4% respectively. Singapore, Malaysia and China are the 3 biggest contributors to the current order book at 59%, 17% and 15% of the total respectively.

### Maintain BUY with a raised TP of RM1.72

We maintain our **BUY** call and raise our target price to RM1.72 (from RM1.60) after rolling forward our valuation horizon to 2020E, based on an unchanged 16x PER. Despite the recent slowdown in China, Singapore continues to make up for the shortfall, while the industrial gas business continues to be the company's long-term attraction, once the LCO2 plant comes on stream by end-3Q19.

### Earnings & Valuation Summary

FYE 31 Dec	2017A	2018A	2019E	2020E	2021E
Revenue (RMm)	313.3	349.2	409.5	516.7	613.1
EBITDA (RMm)	24.8	32.8	39.1	52.1	60.7
Pretax profit (RMm)	16.8	24.5	33.2	43.1	51.8
Net profit (RMm)	10.9	18.5	24.7	33.1	39.7
EPS (sen)	4.8	6.0	8.0	10.7	12.9
PER (x)	26.0	20.7	15.0	11.6	9.6
Core net profit (RMm)	17.2	23.7	25.5	33.1	39.7
Core EPS (sen)	7.5	7.7	8.3	10.7	12.9
Core EPS growth (%)	(2.7)	2.1	7.8	29.4	20.0
Core PER (x)	16.5	16.1	15.0	11.6	9.6
Net DPS (sen)	1.0	1.2	2.5	3.0	3.5
Dividend Yield (%)	0.8	1.0	2.0	2.4	2.8
EV/EBITDA (x)	10.2	11.3	8.5	6.2	5.1
Chg in EPS (%)			(1.5)	(2.8)	0.7
Affin/Consensus (x)			1.06	1.14	1.17

Source: Company, Affin Hwang forecasts, Bloomberg

## Results Note

# Kelington

KGRB MK  
Sector: Oil & Gas

**RM1.24 @ 23 May 2019**

**BUY (maintain)**

Upside: 39%

**Price Target: RM1.72**

Previous Target: RM1.60



## Price Performance

	1M	3M	12M
Absolute	2.5%	3.2%	-1.0%
Rel to KLCI	3.7%	8.2%	13.5%

## Stock Data

Issued shares (m)	294.0
Mkt cap (RMm)/(US\$m)	364.6/87
Avg daily vol - 6mth (m)	1.7
52-wk range (RM)	0.73-1.41
Est free float	43.1%
BV per share (RM)	0.39
P/BV (x)	3.14
Net cash/ (debt) (RMm) (1Q19)	76.5
ROE (2019E)	18.7%
Shariah Compliant	Yes

## Key Shareholders

Palace Star	28.8%
Sun Lead International	6.7%
KWAP	5.5%

Source: Affin Hwang, Bloomberg

Tan Jianyuan, ACCA  
(603) 2146 7538  
jianyuan.tan@affinhwang.com

Outthink. Outperform.

**Downside risks**

The key downside risks to our call include a slowdown in the semiconductor sector, increased price competition, and a breakdown in trade negotiations between the US and China.

**Fig 1: Results comparison**

FYE 31 Dec (RM m)	1Q18	4Q18	1Q19	qoq % chg	yoy % chg	Comments
Revenue	86.5	109.8	76.4	(30.4)	(11.7)	Revenue decreased by 12% yoy, mainly due to a decrease in contribution from China as a result of lower recognition from a UHP project in China
Op costs	(80.9)	(100.4)	(68.2)	(32.1)	(15.7)	
EBITDA	5.6	9.4	8.2	(12.6)	45.3	
<i>EBITDA margin (%)</i>	<i>6.5</i>	<i>8.6</i>	<i>10.7</i>	<i>2.2ppt</i>	<i>4.2ppt</i>	Projects from Singapore contributed to better blended EBITDA margin
Depn and amort	(0.3)	(0.6)	(0.6)	(7.1)	44.6	
EBIT	5.3	8.8	7.6	(12.9)	45.4	
<i>EBIT margin (%)</i>	<i>6.1</i>	<i>8.0</i>	<i>10.0</i>	<i>2ppt</i>	<i>3.9ppt</i>	
Int expense	(0.3)	(0.3)	(0.3)	32.4	12.1	
Int and other inc	0.0	0.0	0.0	<i>n.m</i>	<i>n.m</i>	
Associates	0.0	0.0	0.0	<i>n.m</i>	<i>n.m</i>	
EI	1.6	(1.6)	(0.8)	(50.1)	<i>n.m</i>	RM0.6m unrealised forex loss and RM0.2m impairment on trade receivables
<b>Pretax profit</b>	<b>6.4</b>	<b>6.9</b>	<b>6.5</b>	(6.1)	1.1	
<b>Core pretax</b>	<b>4.9</b>	<b>8.5</b>	<b>7.3</b>	(14.3)	47.4	
Tax	(2.2)	(1.9)	(1.7)	(9.3)	(22.9)	
<i>Tax rate (%)</i>	<i>34.8</i>	<i>27.5</i>	<i>26.5</i>	<i>-0.9ppt</i>	<i>-8.3ppt</i>	
MI	0.0	0.2	0.1	<i>n.m</i>	<i>n.m</i>	
<b>Net profit</b>	<b>4.2</b>	<b>5.2</b>	<b>4.8</b>	(6.9)	15.0	
EPS (sen)	1.8	2.1	1.9	(6.9)	5.3	
<b>Core net profit</b>	<b>2.7</b>	<b>6.8</b>	<b>5.6</b>	(17.1)	>100	Core net profit was within consensus and our expectations at 22% of 2019 full-year estimates

Source: Affin Hwang, Company

**Fig 2: Segmental and geographical revenue breakdown (RMm)**

	1Q18	2Q18	3Q18	4Q18	1Q19	qoq % chg	yoy % chg
Ultra High Purity	63.3	75.0	37.9	50.2	44.0	(12.2)	(30.5)
Process Engineering	14.5	9.5	15.5	35.2	20.8	(40.9)	43.0
General Contracting	8.0	3.7	9.7	23.0	10.3	(55.4)	28.3
Industrial Gases	0.6	1.0	0.6	1.4	1.3	(7.1)	100.9
<b>TOTAL</b>	<b>86.5</b>	<b>89.2</b>	<b>63.7</b>	<b>109.8</b>	<b>76.4</b>	<b>(30.4)</b>	<b>(11.7)</b>

	1Q18	2Q18	3Q18	4Q18	1Q19	qoq % chg	yoy % chg
Malaysia	22.7	19.9	20.3	51.5	21.5	(58.2)	(5.2)
Singapore	13.6	26.2	25.7	46.2	31.1	(32.7)	127.7
China	46.7	39.7	12.5	8.3	22.1	164.7	(52.8)
Taiwan	3.2	2.8	4.6	2.0	1.5	(24.1)	(52.8)
Indonesia	0.3	0.7	0.7	1.8	0.3	(85.8)	(7.0)
<b>TOTAL</b>	<b>86.5</b>	<b>89.2</b>	<b>63.7</b>	<b>109.8</b>	<b>76.4</b>	<b>(30.4)</b>	<b>(11.7)</b>

Source: Affin Hwang, Company

## Important Disclosures and Disclaimer

### Equity Rating Structure and Definitions

<b>BUY</b>	Total return is expected to exceed +10% over a 12-month period
<b>HOLD</b>	Total return is expected to be between -5% and +10% over a 12-month period
<b>SELL</b>	Total return is expected to be below -5% over a 12-month period
<b>NOT RATED</b>	Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a recommendation

*The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.*

<b>OVERWEIGHT</b>	Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months
<b>NEUTRAL</b>	Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months
<b>UNDERWEIGHT</b>	Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, its associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Any opinions or estimates in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by:  
 Affin Hwang Investment Bank Berhad (14389-U)  
 A Participating Organisation of Bursa Malaysia Securities Berhad

22nd Floor, Menara Boustead,  
 69, Jalan Raja Chulan,  
 50200 Kuala Lumpur, Malaysia.

T : + 603 2146 3700  
 F : + 603 2146 7630  
[research@affinhwang.com](mailto:research@affinhwang.com)

[www.affinhwang.com](http://www.affinhwang.com)